Last reviewed · How we verify
ezetimibe with simvastatin — Competitive Intelligence Brief
phase 3
Cholesterol absorption inhibitor and statin
NPC1L1 and HMG-CoA reductase
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
ezetimibe with simvastatin (ezetimibe with simvastatin) — Organon and Co. Ezetimibe inhibits the absorption of cholesterol in the small intestine, while simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ezetimibe with simvastatin TARGET | ezetimibe with simvastatin | Organon and Co | phase 3 | Cholesterol absorption inhibitor and statin | NPC1L1 and HMG-CoA reductase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Cholesterol absorption inhibitor and statin class)
- Organon and Co · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ezetimibe with simvastatin CI watch — RSS
- ezetimibe with simvastatin CI watch — Atom
- ezetimibe with simvastatin CI watch — JSON
- ezetimibe with simvastatin alone — RSS
- Whole Cholesterol absorption inhibitor and statin class — RSS
Cite this brief
Drug Landscape (2026). ezetimibe with simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ezetimibe-with-simvastatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab